LYL1 and acute myeloid leukemia: Therefore, we examined the antitumor activity of GNE-987 on BRD4 in AML and confirmed that it downregulated the expression of many superenhancers and related oncogenes, such as LYL1, to determine an effective strategy for the treatment of children with AML.